These Analysts Slash Their Forecasts On Abivax Following H1 Results

Like
Comment
Favorite

These Analysts Slash Their Forecasts On Abivax Following H1 Results

Benzinga Earnings09-22

Abivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.

The company posted losses of $2.43 per share, compared to the analyst consensus estimate of losses of $1.08 per share. The company reported sales of $2.959 million which beat the analyst consensus estimate of $1.860 million.

Abivax shares fell 0.1% to $103.41 in pre-market trading.

These analysts made changes to their price targets on Abivax following earnings announcement.

Wedbush analyst David Nierengarten maintained the stock with a Neutral and lowered the price target from $140 to $118.
Truist Securities analyst Gregory Renza maintained the stock with a Buy and lowered the price target from $155 to $151.

Considering buying ABVX stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2669147644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669147644","market":"hk","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On Abivax Following H1 Results","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/AAVXF\">Abivax SA</a></strong> (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.</p>\n<p>The company posted losses of $2.43 per share, compared to the analyst consensus estimate of losses of $1.08 per share. The company reported sales of $2.959 million which beat the analyst consensus estimate of $1.860 million.</p>\n<p>Abivax shares fell 0.1% to $103.41 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Abivax following earnings announcement.</p>\n<ul>\n<li>Wedbush analyst David Nierengarten maintained the stock with a Neutral and lowered the price target from $140 to $118.</li>\n<li>Truist Securities analyst Gregory Renza maintained the stock with a Buy and lowered the price target from $155 to $151.</li>\n</ul>\n<p><strong>Considering buying ABVX stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"304\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513-1024x304.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513-1024x304.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513-300x89.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513-768x228.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513.png 1187w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On Abivax Following H1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On Abivax Following H1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-09-22 21:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/AAVXF\">Abivax SA</a></strong> (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.</p>\n<p>The company posted losses of $2.43 per share, compared to the analyst consensus estimate of losses of $1.08 per share. The company reported sales of $2.959 million which beat the analyst consensus estimate of $1.860 million.</p>\n<p>Abivax shares fell 0.1% to $103.41 in pre-market trading.</p>\n<p>These analysts made changes to their price targets on Abivax following earnings announcement.</p>\n<ul>\n<li>Wedbush analyst David Nierengarten maintained the stock with a Neutral and lowered the price target from $140 to $118.</li>\n<li>Truist Securities analyst Gregory Renza maintained the stock with a Buy and lowered the price target from $155 to $151.</li>\n</ul>\n<p><strong>Considering buying ABVX stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"304\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513-1024x304.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513-1024x304.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513-300x89.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513-768x228.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/22092626/image-513.png 1187w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/09/61919671/these-analysts-slash-their-forecasts-on-abivax-following-h1-results","article_id":"2669147644","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669147644","pubTimestamp":1790083726,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ABVX":"Abivax S.A."},"translate_title":"上半年业绩公布后，这些分析师大幅下调了对 Abivax 的预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"Abivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.\nThe company posted losses of $2.43 per share, compared to the analyst consensus estimate of losses of $1.08 per share. The company reported sales of $2.959 million which beat the analyst consensus estimate of $1.860 million.\nAbivax shares fell 0.1% to $103.41 in pre-market trading.\nThese analysts made changes to their price targets on Abivax following earnings announcement.\n\nWedbush analyst David Nierengarten maintained the stock with a Neutral and lowered the price target from $140 to $118.\nTruist Securities analyst Gregory Renza maintained the stock with a Buy and lowered the price target from $155 to $151.\n\nConsidering buying ABVX stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}